RxDoctor Payments Data

Cynthia Wheeler

Acute Care · Nashville, TNNPI 1265721419

Payments from drug & device makers

$4,856in general payments, 2019–2025

Across 243 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$625
  • Intercept Pharmaceuticals, Inc.$402
  • Ipsen Biopharmaceuticals, Inc$369
  • Madrigal Pharmaceuticals$287
  • plus $154 from 5 others

What the payments were for

  • Food & beverage$4,856100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,856 in reported general payments places this provider in the 90th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$22,506
Medicare patients
144
Services billed
333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir16$383,416
XifaxanRifaximin33$113,755
Sirolimus43$33,546
VemlidyTenofovir Alafenamide12$19,726
Ursodiol58$9,990
Tacrolimus75$6,911
Entecavir17$2,352
Cyclosporine ModifiedCyclosporine, Modified28$2,351
Lactulose30$1,939
Azathioprine52$1,502
Mycophenolate Mofetil32$1,425
Nadolol22$816
Spironolactone38$436
Tenofovir Disoproxil Fumarate19$401
Pantoprazole Sodium17$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$1,513$403,14228 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$625$113,75533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 738 acute care providers in Tennessee.

Other acute care in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →